Brief: Dermapharm Q1 Adj. EBITDA Margin at 33.2%
15/05/2023 06:34
May 15 (Reuters) - Dermapharm Q1 EBITDA margin 30.7%. * Q1 EBITDA EUR 98 million * Q1 adjusted EBITDA margin 33.2% * Q1 adjusted EBITDA EUR 105.8 million * Q1 revenue EUR 319.1 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit